Supplementary Materials

Supplementary Material for:

Therapeutic targeting of casein kinase 1δ in breast cancer

Laura H. Rosenberg, Marie Lafitte, Victor Quereda, Wayne Grant, Weimin Chen, Mathieu Bibian, Yoshihiko Noguchi, Mohammad Fallahi, Chunying Yang, Jenny C. Chang, William R. Roush, John L. Cleveland, Derek R. Duckett*

*Corresponding author. E-mail: ducketdr{at}scripps.edu

Published 16 December 2015, Sci. Transl. Med. 7, 318ra202 (2015)
DOI: 10.1126/scitranslmed.aac8773

This PDF file includes:

  • Fig. S1. CK1δ, but not CK1ε, is overexpressed in human breast cancer and associated with CSNK1D gene amplification.
  • Fig. S2. CK1δ is overexpressed in human breast cancer specimens.
  • Fig. S3. Silencing of CK1δ and CK1ε, but not CK1ε alone, impairs growth and survival of MDA-MB-231 breast cancer cells.
  • Fig. S4. Selective inhibition of FLT3 has no effect on proliferation of MDA-MB-231 breast cancer cells.
  • Fig. S5. Treatment with SR-3029 impairs growth of triple-negative and HER2+ breast tumor models.
  • Fig. S6. Long-term daily dosing with SR-3029 has no adverse effects on major organ histology.
  • Fig. S7. Selective silencing of CK1δ is sufficient to impair growth of MDA-MB-231 breast cancer cells.
  • Fig. S8. Wnt/β-catenin pathway genes are a hallmark of CK1δ-expressing breast cancers.
  • Fig. S9. Constitutively active β-catenin N90 rescues the growth inhibitory effects of CK1δ inhibition and silencing.
  • Fig. S10. CK1δ expression in MCF7 breast cancer cells sensitizes them to SR-3029.
    Fig. S11. Cyclin D1 expression is suppressed in TNBC MDA-MB-231–derived tumors after knockdown of CK1δ.
  • Fig. S12. Inhibition of CK1δ/CK1ε has no effect on intestinal homeostasis.
  • Fig. S13. Canonical Wnt signaling genes are correlated with CK1δ expression in human renal and bladder cancer.
  • Table S1. TCGA RNA-seq and GISTIC2 copy number data and correlation analysis for breast cancer (BRCA) tumors.
  • Table S2. TCGA RNA-seq and GISTIC2 copy number data for basal-like Pam50 breast tumors.
  • Table S3. TCGA RNA-seq and GISTIC2 copy number data for HER2-positive Pam50 breast tumors.
  • Table S4. TCGA RNA-seq and GISTIC2 copy number data for luminal A Pam50 breast tumors.
  • Table S5. TCGA RNA-seq and GISTIC2 copy number data for luminal B Pam50 breast tumors.
  • Table S6. Potency of the CK1δ/CK1ε inhibitor SR-3029 for human breast cancer subtypes.
  • Table S7. No toxic effects from long-term daily treatment with SR-3029.
  • Table S8. TCGA RNA-seq and GISTIC2 copy number data for renal papillary (KIRP) tumors.
  • Table S9. TCGA RNA-seq and GISTIC2 copy number data for bladder cancer (BLCA) tumors.
  • Table S10. Renal papillary cell carcinoma correlation analysis.
  • Table S11. Bladder cancer correlation analysis.
  • Table S12. Wnt signaling genes significantly associated with CK1δ expression in renal papillary cell carcinoma.
  • Table S13. Wnt signaling genes significantly associated with CK1δ expression in bladder cancer.
  • Table S14. Oligonucleotides used for qPCR.
  • Table S15. siRNA sequences.
  • Table S16. shRNA sequences.

[Download PDF]